Therapeutic Strategies to Target the Androgen Receptor
dc.contributor.author | Xiang, W | |
dc.contributor.author | Wang, S | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-01-23T21:14:18Z | |
dc.date.available | 2024-01-23T21:14:18Z | |
dc.date.issued | 2022-07-14 | |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/35786895 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/192127 | en |
dc.description.abstract | The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | American Chemical Society (ACS) | |
dc.subject | Androgen Antagonists | |
dc.subject | Androgen Receptor Antagonists | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.subject | Receptors, Androgen | |
dc.title | Therapeutic Strategies to Target the Androgen Receptor | |
dc.type | Article | |
dc.identifier.pmid | 35786895 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/192127/2/xiang-wang-2022-therapeutic-strategies-to-target-the-androgen-receptor.pdf | |
dc.identifier.doi | 10.1021/acs.jmedchem.2c00716 | |
dc.identifier.doi | https://dx.doi.org/10.7302/22127 | |
dc.identifier.source | Journal of Medicinal Chemistry | |
dc.description.version | Published version | |
dc.date.updated | 2024-01-23T21:14:16Z | |
dc.identifier.orcid | 0000-0002-8782-6950 | |
dc.identifier.volume | 65 | |
dc.identifier.issue | 13 | |
dc.identifier.startpage | 8772 | |
dc.identifier.endpage | 8797 | |
dc.identifier.name-orcid | Xiang, W | |
dc.identifier.name-orcid | Wang, S; 0000-0002-8782-6950 | |
dc.working.doi | 10.7302/22127 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.